Lipocine Inc. (LPCN)
$1.62-2.41%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $9M
- Beta
- 0.47
- P/E (TTM)
- -0.87
- Short % float
- 1.73%
- Days to cover
- 2.3
- SI change
- -1.6%
- 1W
- -22.86%
- 1M
- -27.03%
- vs SPY 1W
- -22.72%
- vs SPY 1M
- -29.53%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 5
- GROWTH
- 23
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-38.8%
REV YoY-
ROE-64.7%
EPS YoY-
ROA-49.7%
GROSS98
OP-801
NET-755
[VALUATION]
P/E TTM-0.87
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.61
P/FCF-
EV/EBITDA-0.71
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO11.48
ND/EBITDA-
BETA0.47
Company news
FAQ
- What is LOPJLB’s current signal on LPCN?
- LOPJLB’s latest quantitative signal on Lipocine Inc. (LPCN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LPCN in?
- Lipocine Inc. (LPCN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Lipocine Inc. (LPCN) do?
- Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost i…